Original Article

You have full text access to this OnlineOpen article

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

Potential for decreased toxicity and combination with biologic therapy

  1. Roy S. Herbst M.D., Ph.D.1,†,*,
  2. Fadlo R. Khuri M.D.1,
  3. Charles Lu M.D.1,
  4. Diane D. Liu M.S.2,
  5. Frank V. Fossella M.D.1,
  6. Bonnie S. Glisson M.D.1,
  7. Katherine M. W. Pisters M.D.1,
  8. Dong M. Shin M.D.3,
  9. Vassiliki A. Papadimitrakopoulou M.D.1,
  10. Jonathan M. Kurie M.D.1,
  11. George Blumenschein Jr. M.D.1,
  12. Merrill S. Kies M.D.1,
  13. Ralph Zinner M.D.1,
  14. Maria S. Jung B.S.N.4,
  15. Robert Lu B.S.N.1,
  16. J. Jack Lee M.D.2,
  17. Reginald F. Munden M.D.5,
  18. Waun Ki Hong M.D.1,
  19. Jin Soo Lee M.D.1

Article first published online: 11 JUL 2002

DOI: 10.1002/cncr.10629

Issue

Cancer

Cancer

Volume 95, Issue 2, pages 340–353, 15 July 2002

Additional Information

How to Cite

Herbst, R. S., Khuri, F. R., Lu, C., Liu, D. D., Fossella, F. V., Glisson, B. S., Pisters, K. M. W., Shin, D. M., Papadimitrakopoulou, V. A., Kurie, J. M., Blumenschein, G., Kies, M. S., Zinner, R., Jung, M. S., Lu, R., Lee, J. J., Munden, R. F., Hong, W. K. and Lee, J. S. (2002), The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer, 95: 340–353. doi: 10.1002/cncr.10629

Author Information

  1. 1

    Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

  3. 3

    University of Pittsburgh, Pittsburgh, Pennsylvania

  4. 4

    Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

  5. 5

    Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 796-8655

*The University of Texas M.D. Anderson Cancer Center, Box 432, 1515 Holcombe Boulevard; Houston, Texas 77030-4009

Publication History

  1. Issue published online: 11 JUL 2002
  2. Article first published online: 11 JUL 2002
  3. Manuscript Accepted: 19 FEB 2002
  4. Manuscript Revised: 9 JAN 2002
  5. Manuscript Received: 13 NOV 2001

Funded by

  • Eli Lilly and Company
  • American Society of Clinical Oncology (ASCO) Career Development Award

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (545K)

REFERENCES

  • 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. Ca Cancer J Clin. 2002; 52: 23–47.
    Direct Link:
  • 2
    Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: DeVitaVT, HellmanS. RosengergSA, editors. Cancer: principles and practice of oncology. 4th ed. New York, NY, 1994: 673–722.
  • 3
    Schottenfield D. Etiology & Epidemiology of lung cancer. In: PassHI, MitchellJB, JohnsonDH, et al, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven: 2000: 367–388.
  • 4
    Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol. 1993; 11: 1866–1872.
  • 5
    Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993; 342: 19–21.
  • 6
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899–909.
  • 7
    Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol. 1993; 11: 1391–1402.
  • 8
    Huang P, Chubb S, Hertel LW, et al. Mechanism of action of 2′,2′difluorodeoxycytidine triphosphate on DNA synthesis. Proc ASCO. 1990; 31: 426.
  • 9
    Hertel L, Kroin J, Misner J, et al. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem. 1988; 53: 2406–2409.
  • 10
    Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anti cancer Drugs. 1995; 6 (Suppl 6): 19–25.
  • 11
    Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999; 17: 12–18.
  • 12
    Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17: 3522–3530.
  • 13
    Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000; 18: 122–130.
  • 14
    Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol. 1989; 16 (2 Suppl 4 ): 2–4.
  • 15
    Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol. 1989; 16 (2 Suppl 4 ): 5–8.
  • 16
    Lonardi F, Pavanoto G, et al. Vinorelbine as single-agent chemotherapy in advanced non-small cell lung cancer. Proc ASCO. 1994; 13: 1123a.
  • 17
    Furuse K, Kubota K, Kawahara M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer. 1994; 11: 385–391.
  • 18
    Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A Phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 1991; 14: 115–119.
  • 19
    Carrato A, Rosell R, Camps C, et al. Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer. 1997; 17: 261–269.
  • 20
    Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12: 360–367.
  • 21
    Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16: 2459–2465.
  • 22
    Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210–3218.
  • 23
    Gridelli C. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999; 91: 66–72.
  • 24
    Herbst RS, Lynch C, Vasconcelles M, et al. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001; 48: 151–159.
  • 25
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 1–10.
  • 26
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18: 2529–2536.
  • 27
    Gridelli C, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer Study) Phase III trial: gemcitabine + vinorelbine vs. vinorelbine and vs. gemcitabine in elderly advanced NSCLC patients [abstract]. Proc ASCO. 2001; 20; 308a (abstr 1230).
  • 28
    Lorusso V, Carpagnano F, Frasci G, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol. 2000; 18: 405–411.
  • 29
    Lilenbaum R, Cano R, Schwartz M, et al. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: a Phase II study. Cancer. 2000; 88: 557–562.
    Direct Link:
  • 30
    Gridelli C, Frontini L, Perrone F, et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a Phase II study of three different doses. Gem Vin Investigators. Br J Cancer. 2000; 83: 707–714.
  • 31
    Hainsworth JD, Burris HA, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinoma patients: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2000; 88: 1353–1358.
    Direct Link:
  • 32
    Barr F, Mirsky H, Clinthorne D, Bendel S, Smith P. A Phase III study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small cell lung cancer. Proc ASCO. 1999; 18: 496a (abstr 1914).
  • 33
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002; 346: 92–98.
  • 34
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095–2103.
  • 35
    Fossella FV, DeVore R, Kerr RN, et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000; 18: 2354–2362.
  • 36
    Georgoulias V, Samonis G, Papadakis E, et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer. 2001; 34 () Suppl 4: 47–51.
  • 37
    Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel (taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer [review]. Semin Oncol. 2001; 28 (1 Suppl 2 ): 15–21.
  • 38
    Kosmidis P. Interim results of a Phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small cell lung cancer. Oncology (Higuntingt). 2000; 14 (7 Suppl 4 ): 41–48.
  • 39
    Thompson D, Hainsworth J, Burris H III, Erland J, et al. Prospective randomized study of four third generation chemotherapy regimens in patients with advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network [abstract]. Proc ASCO. 2001; 20: 314a.
  • 40
    Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17: 3631–3652.
  • 41
    Khuri FR, Glisson BS, Meyers ML, et al. Phase I study of farnesyl transferase inhibitor SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety [abstract]. Proc ASCO. 2000; 19: 205a.
  • 42
    Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer. 1995; 31A: 178–183.
  • 43
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000; 6: 4885–4892.
  • 44
    Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa™), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: evidence of activity and good tolerability [abstract]. Proc ASCO. 2000; 19: 177a.
  • 45
    DeVore R, Fehrenbacher L, Herbst RS, et al. A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIb/IV NSCLC [abstract]. Proc ASCO. 2000; 19: 485.
  • 46
    Herbst RS, Khuri FR, Fossella FV, et al. ZD1839 (Iressa™) in non-small cell lung cancer. Clin Lung Cancer. 2001; 3: 27–32.
  • 47
    Esteban E, Llano J, Vieitez J, et al. Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Proc ASCO. 1998; 17: 482a (abstr 1855).
  • 48
    Gridelli C, Cigolari S, Gallo C, et al. an abstract. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001; 31: 277–284.
  • 49
    Beretta GD, Michetti G, Belometti MO, et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer. 2000; 83: 573–576.
  • 50
    Bajetta E, Chiara Stani S, De Candis D, et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial. Cancer. 2000; 89: 763–768.
    Direct Link:
  • 51
    Chen YM, Perng RP, Yang KY, et al. A multicenter Phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest. 2000; 117: 1583–1589.
  • 52
    Feliu J, Lopez Gomez L, Madronal C, et al. Gemcitabine plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer. 1999; 86: 1463–1469.
    Direct Link:
  • 53
    Baron F, Cueva J, Grana B, et al. Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. Eur J Cancer. 2001; 37: 1381–1384.
  • 54
    Laack E, Mende T, Benk J, et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer. A Phase II trial. Eur J Cancer. 2001; 37: 583–590.
  • 55
    Krajnik G, Mohn-Staudner A, Thaler J, et al. Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC Phase II trial. Austrian Association for the Study of Lung Cancer. Ann Oncol. 2000; 11: 993–998.
  • 56
    Isokangas OP, Knuuttila A, Halme M, et al. Phase II study of vinorelbine and gemcitabine for inoperable Stage IIIB-IV non-small-cell lung cancer. Ann Oncol. 1999; 10: 1059–1063.
  • 57
    Hirsh V, Langleben A, Ayoub J, Cormier Y, Pintos J, Iglesias JL. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a Phase II multicenter trial. Cancer. 2001; 92: 830–835.
    Direct Link:
  • 58
    Herrero CC, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer. 2000; 27: 47–53.
View Full Article (HTML) Get PDF (545K)